CBIA Canopus Biopharma Inc (PK)

Canopus BioPharma Inc. (OTCPK: CBIA) today announced it has commissioned a team of experts led by Dr. Akihiro Shimosaka, to assist with its plans for major collaborations to license, manufacture and distribute its H1N1 Swine flu statin antiviral. This team is currently in negotiations with the Office of Disease Control and Emergency Response, the CDC and the SFDA in China with a view to initiating large scale clinical trials and gaining marketing approval on behalf of Canopus BioPharma.

Canopus has patented and developed novel aerosol formulations of the widely used cholesterol lowering drugs statins, which Canopus has proved effective against all previous pandemic strains of influenza. This formulation will provide a new approach to combat the recent threat of a Swine flu pandemic. The objective of Canopus� newly appointed scientific and commercial panel is to launch aerosol statin formulations as viable antiviral medications to target all strains of influenza. �We believe that statins hold the key to mass treatment of influenza pandemics in humans. It is also expected that this aerosol formulation will demonstrate a high degree of efficacy against H1N1 Swine flu, as it is a broad spectrum influenza antiviral, having shown efficacy against not only H1N1, H3N2, and H5N1, but also against equine influenza, H3N8 in separate animal studies,� said Patrick Prendergast, Chairman and CEO of Canopus BioPharma.

Canopus� new statin formulation has proven to be as effective as Roche�s Tamiflu, the current prescribed medication for influenza infection, in a number of Canopus BioPharma sponsored animal studies. There is a need for novel anti-influenza antivirals to overcome the development of drug resistance associated with current prescription antiviral medications for influenza. Also, the effectiveness of Tamiflu is undermined when administered more than 48 hours after infection. Findings published in 2005 noted that four out of eight patients treated for influenza infection in Vietnam died despite the use of Tamiflu1, 4. However Canopus� statin formulation maintains its efficacy even when administered 48 hours post infection.

Statins are the most commonly prescribed drugs worldwide and due to their low toxicity can be administered as a prophylactic. There is a considerable amount of support for the use of statins as an influenza remedy. In 2007, it was found that statins dramatically reduced the risk of influenza deaths2. A global influenza expert noted that statins may improve outcomes in influenza patients; statins are inexpensive, can be stockpiled and would be available on the first pandemic day3.

Research carried out by Canopus during the past five years, both in the USA and China, identified statins as a powerful and effective formulation for the prevention and treatment of influenza infections, in particular H1N1, H5N1 and H3N2. H1N1 (Spanish Influenza) and H3N2 (Hong Kong Influenza) were the strains responsible for the pandemics in 1918 and 1968 respectively, which claimed millions of lives. H5N1 is the strain responsible for the 2005 outbreak of avian influenza. Statin formulations significantly reduces influenza viral load and prevents lung tissue damage by lowering the expression of cytokines. The �cytokine storm� is responsible for severe inflammation, a major cause of mortality among influenza patients.

In view of the recent pandemic threat, Canopus BioPharma appreciates the urgency for the development of new influenza treatments and believes this team of industry experts can improve on Canopus� efforts to date. Dr. Prendergast further commented �Canopus has been dedicated to influenza research for the past five years which highlights the foresight and vision of our research team. We are excited by the possibilities and opportunities brought to us by expanding Canopus� team in China and South-east Asia, and are eager to launch aerosol statins as a much needed alternative for influenza prevention and treatment�

The global market demand for influenza antivirals is expected to have a market value of approximately $3.7 billion by 2010.

1-New England Journal of Medicine, 2005; 353(25):2667-2672

2-American College of Chest Physicians 2007; 13:1006-1012

3-Lancet Infectious Diseases, 2008; 8(9):571-576

4-JAMA, 2009; 301(10):1034-1041�Infections with Oseltamivir-Resistant Influenza A (H1N1) Virus in the US

About Canopus BioPharma, Inc.

Canopus BioPharma Inc (OTCPK: CBIA) is dedicated to providing the safest, most cost effective and efficacious pharmaceutical products and assay methods in the areas of infectious disease, radiation protection and cancer. With innovative science, proven research and development leadership and superior products and compounds, Canopus BioPharma has, since 2001 been committed to becoming a market trend setter in a new era of healthcare. In addition, the Company is a world leader in the development of novel camelid antibody products to provide unique avenues of progress and improvement in assay methods and monitoring capabilities for physicians, patients and researchers, particularly for food chain protection applications. Canopus maintains staff in Australia, South Africa, Ireland and the USA. Additional information on the company is available at www.canopusbiopharma.com.

Canopus BioPharma Inc Disclaimer:

With the exception of historical information contained in this press release, content herein may contain �forward looking statements� that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management�s current expectations and are subject to uncertainty and changes in circumstances. In particular, the Company may not be successful in its efforts commercialize or attain acceptable clinical results for its products. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts and research and development programs, uncertainties as a result of research and development, consumer and industry acceptance, litigation and/or court proceedings, regulatory risks including approval of Food and Drug Administration filings, the ability to achieve and maintain revenues and profitability in the Company�s business lines, and other factors discussed in the Company's filings with the Securities and Exchange Commission.

Canopus Biopharma (PK) (USOTC:CBIA)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024

Canopus Biopharma (PK) (USOTC:CBIA)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024